Lynx Investment Advisory’s Amgen AMGN Stock Holding History

Lynx Investment Advisory’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-217	Closed	-$67.9K	–	167
2024 Q2	$67.9K	Buy	+217	New	+$63.8K	0.05%	219

Other funds holding AMGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Lynx Investment Advisory's AMGN Position: Q3 2024 in Review

Lynx Investment Advisory sold out of Amgen (AMGN) in Q3 2024, closing a stake of 217 shares — an estimated $67.9K sold.

Lynx Investment Advisory first reported a position in AMGN in Q2 2024 and held it in 1 quarter. The position peaked at $67.9K in Q2 2024. 2,824 funds tracked by Wall St. Rank hold AMGN as of Q3 2024.

Lynx Investment Advisory reported no remaining Amgen position as of Q3 2024 after selling out during the quarter.
Lynx Investment Advisory sold 217 Amgen shares in Q3 2024, an estimated $67.9K.
Lynx Investment Advisory first reported a position in Amgen in Q2 2024 and held it in 1 quarter.
Lynx Investment Advisory's Amgen position peaked at $67.9K in Q2 2024.
2,824 funds tracked by Wall St. Rank held Amgen as of Q3 2024.

Based on Lynx Investment Advisory's 13F filing for Q3 2024, filed 4 Nov 2024.